Citations

Clear

1792 citation(s) found for "Stephanie".

Assessment of Fairness and Bias of an Image-based Surgical Site Infection Detection AI Model
Lee, Frank G. , Choudhary, Ashok , Li-Han, Leo Yan , Dale, Erica L., Bankes, Audrey C , Varghese, Chris , Anderson, Stephanie S., Habermann, Elizabeth B. , Etzioni, David A. , McLaughlin, Sarah A. , Salehinejad, Hojjat , Thiels, Cornelius A. , Varghese, Chris , Habermann, Elizabeth , Dale, Erica , Bankes, Audrey , Choudhary, Ashok

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.22.26363636 Get It

ABSTRACT Background Evaluating fairness in artificial intelligence (AI) is essential before clinical implementation to prevent unintended harm across diverse patient populations. This study assesses performance differences of an image-based surgical site infection (SSI) detection model across age, gender, geography, race, and skin color. Methods Model development/validation study using retrospective, multicenter data across surgical subspecialties from adults who submitted an image of their incision via the electronic health record within 30 days of their procedure between 2019-2024. Area under receiver operating curve (AUROC) was compared by age (<55 vs. ≥55 years old), gender (male vs. female), geography (Rochester, Minnesota vs. Jacksonville, Florida vs. Scottsdale, Arizona vs. regional Minnesota/Wisconsin areas), race (White/Caucasian vs. non-White/Caucasian), and skin color (Fitpatrick I-III vs. IV-VI and Monk A-E vs. F-J). Results Training data contained 13,702 images from 4,274 patients between 2019-2022 (50.1% ≥55 years old; 63.2% female; 91.6% White/Caucasian; 58.5% Rochester, 17.3% Florida, 10.5% Arizona; 96.3% light skin tone), of which 1,348 images (9.8%) had an SSI. No differences in SSI detection existed for age, gender, race, or skin color (AUROC 0.83-0.87, p>0.09), however geographical differences were significant: lowest AUROC 0.83 (95% CI 0.77-0.88) vs. highest AUROC 0.87 (95% CI 0.84-0.89, p=0.01). Temporal validation using 4,242 images from 1,353 patients between 2022-2023 showed intact fairness across subgroups (ΔAUROC ≤0.06) except geography (ΔAUROC ≤0.16). Conclusions The model behaved fairly across age, gender, race, and skin color, however geographical differences persisted. These findings have practical implications underscoring the importance of evaluating bias in clinical AI before deployment.
Extended normothermic machine perfusion preserves viability and tissue integrity of ex vivo human intestine segments
Urbina, Pamela A. Manco, Choi, Sae Rome, Cheung, Dillon C., Egbert, Lena K. , Garcia-Neuer, Marlene I., Yu, Stephanie, Rehman, Nisha S., Hanks, Danielle G., Le, Tuan‐Anh , Alabay, Husnu H., McHugh, Kelsey , Hamdan, Feda H., Naik, Nimesh, Faubion, William A. , Brady, Justin T. , Ceylan, Hakan , Bose, Suman , Urbina, Pamela Allison Manco , Garcia-Neuer, Marlene , Rehman, Nabeela, Alabay, Husnu Halid , Hamdan, Feda H. , Naik, Nimesh D.

Mayo Clinic

No container title available | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.17.752436 Get It

ABSTRACT Human intestinal diseases, including inflammatory bowel disease (IBD), are difficult to model because existing animal and in vitro systems do not capture the intestine’s integrated vascular, immune, and metabolic complexity. Here, we establish a custom normothermic machine perfusion platform that maintains surgically resected human intestinal tissue for up to 72 hours under near-physiological conditions. Discarded specimens from patients with nonmalignant intestinal diseases, including IBD and diverticulitis, were continuously perfused at 37°C with real-time hemodynamic and metabolic monitoring. Perfusion preserved tissue viability, mucosal architecture, epithelial integrity, oxygen consumption, metabolic activity, and vascular patency. Daily perfusate sampling enabled longitudinal profiling and experimental modulation of inflammatory mediators, revealing patient-specific immune states. This long-duration platform bridges reductionist in vitro models and clinical disease, enabling mechanistic studies of intestinal inflammation and future testing of personalized therapies in intact patient-derived tissue.
A mobile app compared with an educational pamphlet on menopause hormone therapy initiation: a randomized pilot study
Kling, Juliana M., French, Courtney A., Kapoor, Ekta, Hedges, Mary S., Deng, Yihong, Chaudhry, Rajeev, Smith, Jamie L., Cole, Kristin C., Shufelt, Chrisandra , Karens, Arjan, Faubion, Stephanie S., Smith, Jamie L , Kling, Juliana M. , Kapoor, Ekta , Hedges, Mary S. , Paul, Margaret M. , Chaudhry, Rajeev , Castaneda, Regina , Faubion, Stephanie S.

Mayo Clinic

Frontiers in Reproductive Health | September 16, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/frph.2026.1952673 | PMID 42819486 Get It

Background Menopause-related symptoms are common but undertreated. Digital tools that support symptom assessment and patient education may improve engagement. Objective To assess whether a previsit digital menopause symptom assessment and education tool increased treatment initiation and patient engagement compared to an educational pamphlet. Design Women aged 45–55 years with upcoming primary care appointments were invited to participate. Those with a total Menopause Rating Scale (MRS) score ≥5 indicating bothersome menopause symptoms were included. Participants were randomized to a digital menopause symptom assessment tool or a digital educational pamphlet and completed a post-visit survey (NCT06919887). Participants Of the 14,726 women invited to participate between May 12, 2025, and December 5, 2025, there were 653 (4.4%) enrolled that met eligibility criteria. Interventions Randomized to an mHealth app called emmii or a standard digital menopause educational pamphlet. Main measures Menopause treatment initiation within 30 days of the clinical visit was assessed by electronic health data. Baseline and post-visit surveys were collected assessing patient experience, engagement, and perceived usefulness. Rates of menopause hormone therapy (HT) prescribing were compared with a reference population of nonparticipants aged 45–55 who had a primary care appointment at Mayo Clinic during the same period and received no study education materials. Key results Of 653 participants enrolled and randomized, 383 completed both the baseline and post-surveys (171 intervention and 212 control). HT initiation among study participants was significantly higher than in the reference population of women (9.3% vs. 4.4%, p &lt; 0.001). There was no difference in HT initiation between the intervention (9.1%) and control groups (9.6%) ( p = 0.83). Initiation rates were 3.8% and 4.5%, respectively ( p = 0.64) for nonhormone therapies. Conclusions Among women with bothersome menopause symptoms, those who underwent previsit symptom screening and received educational materials had higher rates of HT initiation than women who did not participate in the study. These findings suggest that structured menopause education may improve recognition and management of menopause symptoms in routine clinical practice.
A Novel De Novo STAG1 Variant at the RAD21 Binding Interface Is Associated With Hypoglycemia, Recurrent Fever, Immunodeficiency and Features of Classical Cohesinopathies
Hussain, Hafiz Muhammad Jafar , Zimmermann, Michael T. , Farris, Joseph , Panwar, Deepak , Thurman, Sarah , Muthusamy, Karthik , Wick, Myra , Klee, Eric W. , Zimmermann, Michael T , Safgren, Stephanie L , Farris, Joseph D , Panwar, Deepak , Thurman, Sarah Allen , Muthusamy, Karthik , Urrutia, Raul , Vairo, Filippo , Klee, Eric W , Safgren, Stephanie L. , Urrutia, Raúl , Vairo, Filippo Pinto e

Mayo Clinic

Clinical Genetics | September 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/cge.70246 | PMID 42713681 Get It

ABSTRACT The cohesin complex, composed of SMC1, SMC3, RAD21, and STAG1/STAG2, is essential for chromosome cohesion, DNA repair, and transcriptional regulation. Pathogenic variants in cohesin components cause cohesinopathies. The classical characteristics of cohesinopathies include developmental delay (DD), intellectual disability (ID), feeding difficulties, hypotonia, short stature, hearing loss, and dysmorphic features. Here, we present a 5‐year‐old boy with classical cohesinopathy features, including DD/ID and feeding difficulties, along with non‐classical features such as hypoglycemia, recurrent fever, and immunodeficiency. Trio exome sequencing identified a novel de novo missense variant of uncertain significance (NM_005862.3:c.643G>A(p.Val215Ile)) in the STAG1 gene. The variant localizes to the RAD21 interaction interface, and molecular dynamics (MD) simulations revealed conformational changes comparable to other STAG1 variants reported as likely pathogenic in patients, supporting a deleterious effect which may disrupt the STAG1‐RAD21 interaction interface. This case expands the phenotypic and molecular spectrum of STAG1‐related cohesinopathy and advances our understanding of the disease mechanism.
Menopausal Hormone Therapy and Cardiovascular—Laying the Foundation for Future Trials
Castaneda, Regina, Faubion, Stephanie S., Castaneda, Regina , Faubion, Stephanie S.

Mayo Clinic

JAMA Internal Medicine | September 8, 2026 | Volume: 186 | Issue: 11 | Pages: 1332

10.1001/jamainternmed.2026.2877 | PMID 42709427 Get It

Pearls & Oy-sters: DPPX Antibody-Associated Encephalitis in a Patient With Diarrhea, Tremor, Ocular Flutter, and Cognitive-Psychiatric Changes
Sosa, Santiago Martinez , Webb, Lauren M. , Thomsen, Anna, Rigler, Nicole, Coon, Elizabeth A. , Toledano, Michel , McKeon, Andrew , Banks, Samantha A. , Martinez Sosa, Santiago , Paz Soldán, M Mateo , Coon, Elizabeth Anne , Toledano, Michel , McKeon, Andrew , Syc-Mazurek, Stephanie B , Banks, Samantha , Soldán, M. Mateo Paz , Syc‐Mazurek, Stephanie B.

Mayo Clinic

Neurology | September 1, 2026 | Volume: 107 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000218522 | PMID 42679339 Get It

Brain multiomic profiling identifies tau-related transcriptomic dysregulation in Alzheimer’s disease
Oatman, Stephanie R., Quicksall, Zachary , Wang, Xue, Bergman, Jeremiah, Reddy, Joseph S, Vanelderen, Floor , Nguyen, Thuy , Malphrus, Kimberly, Lincoln, Sarah, Martens, Yuka A. , Zhao, Na, Yamazaki, Yu, DeTure, Michael, Bu, Guojun, Kanekiyo, Takahisa , Allen, Mariet , Ertekin‐Taner, Nilüfer , Lincoln, Sarah J, Murray, Melissa E , Kanekiyo, Takahisa , Dickson, Dennis W , Ertekin-Taner, Nilüfer , Reddy, Joseph S. , Malphrus, Kimberly G., Yamazaki, Yu , DeTure, Michael , Murray, Melissa E. , Liu, Chia‐Chen , Bu, Guojun , Dickson, Dennis W.

Mayo Clinic

Brain Communications | August 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/braincomms/fcag326 | PMID 42712681 Get It

Abstract Identification of gene expression changes in post-mortem brain tissue of Alzheimer’s disease donors compared to controls have implicated numerous biological pathways for Alzheimer’s disease pathophysiology. Nonetheless, there is still limited understanding of how gene expression dysregulation underpins specific proteinopathies core to Alzheimer’s disease. Here we investigate brain transcriptomic changes in a well characterized cohort of Alzheimer’s disease donors to identify genes and networks that associate with Alzheimer’s disease endophenotypes including neuropathology measures (Braak stage, Thal phase and cerebral amyloid angiopathy score) and Alzheimer’s disease-related brain protein levels (Apolipoprotein E, Amyloid-β 40, Amyloid-β 42, tau, and phospho-Tau). Bulk transcriptome measures were collected from the temporal cortex tissue of 477 Alzheimer’s disease donors. Following quality control, transcriptome-wide association studies were performed for each endophenotype. We used weighted gene co-expression network analysis to build co-expression networks and integrated transcriptome with epigenetic and genetic data from the same donors. We detected a total of 5,740 Bonferroni significant temporal cortex gene associations with Alzheimer’s disease endophenotypes, most of which were with brain tau levels. We discovered tau-associated co-expression modules enriched in known and novel Alzheimer’s disease pathways. We found that a beneficial (or neutral) brain biochemical state of higher total tau and lower phospho-Tau are associated with increased levels of synaptic, DNA damage/repair, nucleic acid metabolism and myelin processes. In contrast, in a detrimental state of lower total and higher phospho-Tau, there is upregulation of vascular and immune, and downregulation of mitochondrial and myelin pathways. There are brain gene expression perturbations that are associated with Alzheimer’s disease endophenotypes. While some of these associations are common across multiple endophenotypes, many are distinct for different Alzheimer’s disease-related proteins. Based on these findings, we propose a hypothetical model of dynamic brain gene expression changes that track with progressive Alzheimer’s disease proteostasis. These expression changes hold potential to serve as dynamic, precision biomarkers of brain Alzheimer’s disease progression. This study demonstrates the potential of integrative multiomics and deep Alzheimer’s disease endophenotype analyses in well-characterized brain tissues to uncover with precision the complex biology of Alzheimer’s disease.
TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
The Association of Flavin Mononucleotide and Lactate During Normothermic Regional Perfusion with Post-Transplant Liver Outcomes: An Exploratory Study
Fischer, R , Cywes, Claire , Ong, Olivia , Muñoz, Nicolás , Din, Sardar, Ibeabuchi, Tobenna , Brown‐Soler, Isabela , Mahmud, Nadim , Cederquist, K., Smith, Georgeine, Benko, Stephanie , Wehrle, Chase J. , Sonnenberg, Elizabeth M. , Gazala, Samir Abu , Markmann, James F. , Olthoff, Kim M. , Shaked, Abraham , Vyas, Frederick, Sellers, Marty T. , Jonge, Jeroen de , Sun, Keyue , Schlegel, Andrea , Abt, Peter L. , Fischer, Raphaël M J , Levine, Matthew H , Abu-Gazala, Samir , Markmann, James F , Olthoff, Kim M , Shaked, Abraham , Sellers, Marty , de Jonge, Jeroen , Sun, Keyue , Schlegel, Andrea , Abt, Peter L , Ong, Olivia , Din, Sardar Wali , Vyas, Frederick

Mayo Clinic

Medicina | August 24, 2026 | Volume: 62 | Issue: 9 | Pages: 1622

10.3390/medicina62091622 | PMID 42796229 Get It

Background and Objectives: Normothermic regional perfusion (NRP) is an effective technique to improve recipient outcomes. However, no valid methods for determining liver viability exist. Identifying relevant biological markers with clinical correlation to liver viability and recipient clinical outcomes is imperative to improve decision-making. Materials and Methods: Fifty-four donors undergoing NRP and their recipients were included. FMN was measured at the start, 1 h, and end of NRP. Lactate was measured at the start, 30, 60, and 90 min of NRP. Primary outcomes were early allograft function using the early allograft dysfunction (EAD) criteria and the model for early allograft function (MEAF). Secondary outcomes included the association with donor warm ischemia time (DWIT), stratified by 30 min. Spearman’s rho assessed correlations. Results: Forty (74%) livers were transplanted, with 5 (12.5%) recipients developing EAD and the mean MEAF score was 3.13 (1.49). FMN at all time points was significantly greater in the EAD group compared to the non-EAD group and was significantly correlated with the MEAF score (Peak FMN: rho = 0.507, p = 0.001). FMN during perfusion did not differ between DWIT < and ≥30 min. Lactate levels were similar across all groups and did not discriminate for adverse allograft outcomes. However, lactate levels during perfusion were higher in the DWIT ≥ 30 min group. Conclusions: These findings suggest that during NRP, elevated FMN, but not lactate, is associated with early allograft function.
Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
Greenberg, Steven M. , Iadecola, Costantino , Chou, Sherry , Cogswell, Petrice M, Elkind, Mitchell S.V. , II, William J. Hicks, Le, Caitlin, Levine, Deborah A. , Lipton, Richard B. , Massimo, Lauren, Mohl, Stephanie M. , Snyder, Heather M. , Yaffe, Kristine , Adams, Robert, Agronin, Marc, Atri, Alireza, Bauman, Mary Ann, Bernat, James L., Biffi, Alessandro , Blum, Sonja, Bussiere, Thierry, Carrillo, Maria C., Chiang, Gloria, Cato, Kenrick, Chaitoff, Alexander, Bakken, Suzanne, Schelke, Matthew W. , Cruz‐Flores, Salvador, Derdeyn, Colin, Dhand, Amar, Evans, David A., Gettel, Cameron, Goldstein, Larry B, Grill, Joshua, Kulshrestha, Ambar, Lam, Christine, Lazar, Ronald M. , Li, Hanlin , Madsen, Tracy, Ramanan, Vijay K., McCullough, Louise, Merino, José G., Orjuela, Karen, Guo, Michael, Messe, Steve, Tubiello, Maggie, Ruff, Christian T., Selim, Magdy, Sha, Sharon J., Sheth, Kevin, Stamm, Brian, Buckwalter, Marion, Skylar-Scott, Irina, Lavretsky, Helen, Saver, Jeffrey, Rabinovici, Gil D., VandeVrede, Lawren, Goyal, Manu S., Weisman, David C., Lipton, R.B. , Chou, Sherry H-Y , Seshadri, Sudha , Snyder, Heather M , Yaffe, Kristine , Zachrison, Kori S , Cogswell, Petrice M. , Hicks, William J., Massimo, Lauren , Seshadri, Sudha , Atri, Alireza, Blum, Sonja, Bussière, Thierry , Carlisle, Tara C. , Chaitoff, Alexander , Cruz-Flores, Salvador, Chyou, Janice Y. , Derdeyn, Colin P. , Gettel, Cameron J. , Goldstein, Larry B. , Grill, Joshua D. , Ishii, Makoto , Kulshreshtha, Ambar , Rabinstein, Alejandro A. , Ramanan, Vijay K. , McCullough, Louise D. , Merino, José G. , Messé, Steven R. , Ruff, Christian Thomas , Saklad, Stephen R. , Selim, Magdy H. , Shah, Sachin J. , Stamm, Brian , Buckwalter, Marion S. , Skylar-Scott, Irina A., Rabinovici, Gil D. , VandeVrede, Lawren , Chatterjee, Arindam R , Wunderink, Richard G.

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048108 | PMID 42622140 Get It

Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. Methods The American Heart Association convened 75 multidisciplinary experts for the Amyloid‐Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus‐based guidance for clinicians. Results This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co‐occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision‐making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. Conclusions Building on lessons learned from the establishment of stroke systems of care, the consensus‐based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground‐breaking therapies.